Why the study?
The cost-effectiveness of carotid artery stenting versus carotid endarterectomy from the perspective of payers in Türkiye, considering potential complications, needed assessment.
Does carotid artery stenting improve cost-effectiveness compared to carotid endarterectomy in patients with carotid stenosis?
Does carotid artery stenting improve cost-effectiveness compared to carotid endarterectomy in patients with carotid stenosis?
Carotid endarterectomy is more cost-effective than carotid artery stenting for treating carotid stenosis within the Turkish healthcare system.
Answers are grounded in this paper and cite their sources.
CAE may be favored for cost-effectiveness in Turkish settings; leaves open validation in randomized trials elsewhere.
Objective: This study assesses the cost-effectiveness of carotid artery stenting (CAS) versus carotid endarterectomy (CAE) from the perspective of payers in Türkiye, considering potential complications. Methods: A decision tree analysis model was employed using data from 61 patients (29 CAS, 32 CAE) treated for carotid stenosis (CS) between 2019-2021. The procedural costs were derived from a university hospital-billing department, while health outcomes such as any stroke and myocardial infarction (MI) and their utility values were based on meta-analyses and established studies. The primary outcome measure was the incremental cost-effectiveness ratio (ICER). Results: When the model was applied, CAS incurred higher costs ( USD per patient) compared to CAE (USD 947,30), resulting in an ICER of USD 96.345 per QALY. CAE, as a traditional model, demonstrated dominance due to its lower costs and slightly better outcomes. Sensitivity analysis showed that a ±10% change in input parameters, particularly a higher impact was observed in costs and stroke incidence and could alter the ICER about ± USD 1.225 to 3.500. Budget impact analysis estimated CAS and CAE affecting 4.37% and 3.09% of the healthcare budget, respectively. Conclusion: CAE demonstrated superior cost-effectiveness over CAS in treating CS within the Turkish healthcare system. Despite CAS's appeal as a less invasive option, its higher costs and marginal effectiveness suggest that CAE should be prioritized unless parameters such as procedural costs and any stroke risks associated with CAS are reduced.
No takes yet. Share an insight, caveat, or question.
AYDEMİR et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: